CTOs on the Move

AMPAC Fine Chemicals

www.ampacfinechemicals.com

 
AMPAC Fine Chemicals (AFC) manufactures active pharmaceutical ingredients (APIs) and registered intermediates for customers in the pharmaceutical industry. Our integrated facilities are located in Rancho Cordova, California, approximately 20 miles east
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

OpenTrons

We make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other`s results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century`s most important questions.

CODA Biotherapeutics

CODA Biotherapeutics` revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable `switch` protein. Cells modified with the `switch` can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

Pendulum Therapeutics

Pendulum is committed to developing novel interventions that target the human microbiome to improve the lives of patients suffering from a variety of diseases. Our targeted formulations of natural bacterial strains help to rebalance the microbiome which restores and improve one`s health.

Resilience Technology Corporation

Resilience is changing the way medicine is made – leveraging innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.

iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.